interventions lie on or even beyond the boundaries of human skills as they pose extreme requirements in terms of manipulation and positioning precision. As a result, current treatments are characterized by moderate success rates and even an inability to adequately treat some common diseases. As a consequence, a large group of patients is left untreated or receives suboptimal treatment only. Robotic technology can and is likely to put an end to the current status−quo. Starting from existing hardware, knowledge and IP and in close collaboration with medical partners, EurEyeCase will build up and validate a convincing robot−assisted operation suite, which will help surgeons in treating a selection of particular demanding vitreoretinal procedures including the treatment of retinal vein/artery occlusion through cannulation and epiretinal membrane treatment. Current laboratory setups will be studied in detail, augmented and tailored for successful integration into the surgical workflow. Novel sensing technologies will be further developed and integrated with advanced control methods to deliver unprecedented levels of safety and performance. In-depth evaluation of the setup in different directions, i.e, performance, usability and clinical relevance, as well as the first steps to transfer the most challenging developments to the next phase of product development are key aspects of the project. EurEyeCase will demonstrate how medical robotics technology can boost success rates of urgent and critical surgical interventions and paves the way for novel promising treatment methods with demonstrated improvements in patient outcome